Literature DB >> 3278442

Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells.

J Gugenheim1, B Le Thai, P Rouger, M Gigou, P Gane, M C Vial, B Charpentier, M Reynes, H Bismuth.   

Abstract

Liver allografts have a privileged status with regard to hyperacute rejection. In this experimental study, we have used extracorporeal liver hemoperfusion in sensitized rats in order to analyze reactions between lymphocytotoxic antibodies and the liver. In sensitized BN rats, a donor-specific (Lewis) extracorporeal liver hemoperfusion can delay hyperacute rejection of heart allografts and reduce the level of lymphocytotoxic antibodies. The decrease in the level of antibodies could be due to massive absorption of antibodies by the liver or to release of major histocompatibility complex antigens in a soluble form. Immunofluorescent examination of the hemoperfused liver revealed important deposits of C3 on Kupffer cells and of IgG on sinusoidal cells. On the contrary, in control rats in which a third-party (DA) liver hemoperfusion was performed, heart allograft survival was less prolonged, the decrease in the level of lymphocytotoxic antibodies was not significant, and the deposits of IgG and C3 were much less evident. The level of circulating immune complexes was unchanged after a donor-specific or a third-party liver hemoperfusion. These results support the hypothesis that resistance of the liver to hyperacute rejection might be due to a massive and nontoxic absorption of lymphocytotoxic antibodies on nonparenchymal liver cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278442     DOI: 10.1097/00007890-198802000-00046

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model.

Authors:  K Nakamura; N Murase; M J Becich; T Furuya; S Todo; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

Review 2.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

3.  Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury.

Authors:  S Kakizoe; K Yanaga; T E Starzl; A J Demetris
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

4.  The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors.

Authors:  S Takaya; O Bronsther; Y Iwaki; K Nakamura; K Abu-Elmagd; A Yagihashi; A J Demetris; M Kobayashi; S Todo; A G Tzakis
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

5.  Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance.

Authors:  R Mañez; R H Kelly; M Kobayashi; S Takaya; O Bronsther; D Kramer; R J Duquesnoy; Y Iwaki; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

6.  A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies.

Authors:  A J Demetris; K Nakamura; A Yagihashi; Y Iwaki; S Takaya; G G Hartman; N Murase; O Bronsther; R Manez; J J Fung
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

Review 7.  The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives.

Authors:  Elaine Y Cheng
Journal:  J Immunol Res       Date:  2017-01-09       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.